Clinical Trials

There
are 2 clinical trials
for uterine corpus leiomyosarcoma, of which 1
is
open and 1
is
completed or closed.
Of the
trials that contain
uterine corpus leiomyosarcoma as an inclusion criterion, 2 are phase 2 (1 open).

Gemcitabine, olaparib, and pazopanib
are the most common
interventions in
uterine corpus leiomyosarcoma clinical trials.

References

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.